GILD

Gilead Sciences

Halal Rating :
Uncomfortable
Last Price $91.79 Last updated:
Market Cap $114.46b
7D Change 2.06%
1 Year Change 17.03%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Biological Products
  • Except Diagnostic Substances
Exchange Nasdaq
Next Earnings Date Nov. 7, 2024

Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes medicines. The company focuses on antiviral drugs used in the treatment of HIV/AIDS, liver diseases, cancer, and other medical conditions. Their portfolio includes breakthrough treatments for HIV, hepatitis B, hepatitis C, and cell therapy products for cancer treatment.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $7.54b $6.89b - $238.0m 0.00% 3.45%
June 30, 2024 $6.95b $4.55b - $237.0m 0.00% 5.21%
March 31, 2024 $6.69b $11.26b - $254.0m 0.00% 2.26%

Company Impact

Help us evaluate Gilead Sciences's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates